Related Experiment Videos
Soluble interleukin-2 receptor in cancer
1Department of Surgery, Saitama Medical School, Morohongo 38, Moyorama-machi, Iruma-gunn,Saitama, 350-0495, Japan. smurakam@saitama-med.ac.jp
Frontiers in Bioscience : a Journal and Virtual Library
|September 9, 2004
Summary
Serum soluble interleukin-2 receptor (sIL-2R) levels indicate activated T lymphocytes in cancer. Elevated sIL-2R aids in assessing cancer stage and monitoring disease progression.
Area of Science:
- Immunology
- Oncology
Background:
- Soluble interleukin-2 receptor (sIL-2R) is released into circulation when interleukin-2 (IL-2) binds to its receptor on activated T lymphocytes.
- Elevated serum sIL-2R levels are frequently observed in patients with various malignant diseases compared to healthy individuals.
Purpose of the Study:
- To investigate the clinical utility of serum sIL-2R as a biomarker in cancer.
- To assess the correlation between serum sIL-2R levels and cancer disease stage and progression.
Main Methods:
- Measurement of serum sIL-2R levels in cancer patients and healthy controls.
- Analysis of sIL-2R levels in relation to tumor-infiltrating lymphocytes and metastatic organ involvement.
Main Results:
- Serum sIL-2R levels were significantly elevated in most malignant diseases compared to normal controls.
- sIL-2R levels reflect the extent of activated T lymphocytes within tumor tissues and metastatic sites.
Conclusions:
- Serum sIL-2R is a valuable non-organ-specific biomarker for evaluating cancer disease stage.
- Monitoring serum sIL-2R levels can aid in tracking disease progression during post-treatment follow-up.